Author's View www.landesbioscience.com oncoimmunology e28850-1

Author's View The immune system plays a pivotal role in modulating the occurrence and progression of colorectal cancer (CRC).1,2 Various prior studies have shown an asso-ciation between the number of tumor-infiltrating lymphocytes (TILs) and colorectal cancer prognosis, particularly in early-stage tumors.3 Surprisingly, the molecular architecture underlying this phenomenon has yet to be identified and further, the site at which tumor antigen recognition and subsequent presentation occurs, a process critical for the activa-tion of anticancer immune effectors, i